RPB researchers honored with 2018 António Champalimaud Vision Award
Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research
Groundbreaking Gene Therapy for Retinal Disease
The first patient receives an FDA-approved gene therapy for inherited retinal disease at Mass. Eye and Ear.
Reversing Retinal Degenerative Diseases: We’re One Step Closer
RPB-supported researchers made a critical discovery about the gene mutation that causes many retinal degenerative diseases, opening the door for a new line of research into potential treatments.
Edited Stem Cells Offer Hope for RP Therapy
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue
New Gene Therapy for Vision Loss from a Mitochondrial Disease
New method for delivering corrective genes to restore energy production in cells could have wide application.
Renewed Hope for Gene Therapy to Restore Vision
Findings indicate that retinitis pigmentosa is treatable even at advanced disease stages.
A Passion Fueled By RPB
The Neitzes are internationally recognized for developing a potential gene therapy cure for color blindness and are among the world’s thought leaders on genetic and environmental factors that may be influencing a global epidemic of myopia...
Subscribe
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
| General Info | Grants | News & Resources |
Research to Prevent Blindness
360 Lexington Avenue, 22nd Floor
New York, NY 10017
(212) 752-4333
Copyright © 2024 Research to Prevent Blindness. All Rights Reserved.
